CNS Drugs

, Volume 17, Issue 15, pp 1109–1117 | Cite as

Treatment of Recurrent Depression

A Sequential Psychotherapeutic and Psychopharmacological Approach
  • Giovanni A. Fava
  • Chiara Ruini
  • Nicoletta Sonino
Therapy in Practice

Abstract

The chronic and recurrent nature of major depressive disorder is receiving increasing attention.

Approximately eight of ten people experiencing a major depressive episode will have at least one more episode during their lifetime, i.e. recurrent major depressive disorder.

In the 1990s, prolonged or lifelong pharmacotherapy emerged as the main therapeutic tool for preventing relapses of depression. This therapeutic approach is based on the effectiveness of antidepressant drugs compared with placebo in decreasing relapse risk and on the improved tolerability profile of the newer antidepressants compared with their older counterparts. However, outcome after discontinuation of antidepressant therapy does not seem to be affected by the duration of administration. Loss of clinical effects, despite adequate compliance, has also emerged as a vexing clinical problem.

The use of intermittent pharmacotherapy with follow-up visits is an alternative therapeutic option. This leaves patients with periods free of drugs and adverse effects and takes into account that a high proportion of patients would discontinue the antidepressant anyway. However, the problems of resistance (that a drug treatment may be associated with a diminished chance of response in subsequent treatments in those patients whose symptoms successfully responded to it but who discontinued it) and of discontinuation syndromes are substantial disadvantages of this therapeutic approach.

In recent years, several controlled trials have suggested that sequential use of pharmacotherapy in the treatment of the acute depressive episode and psychotherapy in its residual phase may improve long-term outcome. Patients, however, need to be motivated for psychotherapy, and skilled therapists have to be available.

Despite an impressive amount of research into the treatment of depression, there is still a paucity of studies addressing the specific problems that prevention of recurrent depression entails. It is important to discuss with the patient the various therapeutic options and to adapt strategies to the specific needs of patients.

Notes

Acknowledgements

This article was supported in part by a grant from the ‘Mental Health Evaluation Project’ (Istituto Superiore di Sanità, Rome, Italy) to Dr Fava and by grants from the Consiglio Nazionale delle Ricerche (CNR, Rome, Italy) and Ministero dell’Università e della Ricerca Scientifica e Tecnologica (MURST, Rome, Italy) to Drs Fava and Sonino. The authors have no conflicts of interest to declare.

References

  1. 1.
    Judd LL. The clinical course of unipolar major depressive disorders. Arch Gen Psychiatry 1997; 54: 989–91PubMedCrossRefGoogle Scholar
  2. 2.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  3. 3.
    Depression Guideline Panel. Depression in primary care: Vol. 1 — detection and diagnosis. Rockville (MD): US Department of Health and Human Services, 1993: 31Google Scholar
  4. 4.
    Piccinelli M, Wilkinson G. Outcome of depression in psychiatric settings. Br J Psychiatry 1994; 164: 297–304PubMedCrossRefGoogle Scholar
  5. 5.
    Lin EHB, Katon WJ, Von Korff M, et al. Relapse of depression in primary care. Arch Fam Med 1998; 7: 443–9PubMedCrossRefGoogle Scholar
  6. 6.
    Ramana R, Paykel ES, Cooper Z, et al. Remission and relapse in major depression. Psychol Med 1995; 25: 1161–76PubMedCrossRefGoogle Scholar
  7. 7.
    Fava GA. Subclinical symptoms in mood disorders. Psychol Med 1999; 29: 47–61PubMedCrossRefGoogle Scholar
  8. 8.
    Fava M, Kendler KS. Major depressive disorder. Neuron 2000; 28: 335–41PubMedCrossRefGoogle Scholar
  9. 9.
    Ormel J, Oldehinkel T, Brilman E, et al. Outcome of depression and anxiety in primary care. Arch Gen Psychiatry 1993; 50: 759–76PubMedCrossRefGoogle Scholar
  10. 10.
    American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157 (Apr Suppl.): 1–45Google Scholar
  11. 11.
    Schulberg HC, Katon W, Simon GE, et al. Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines. Arch Gen Psychiatry 1998; 55: 1121–7PubMedCrossRefGoogle Scholar
  12. 12.
    Hollon SD, Shelton RC. Treatment guidelines for major depressive disorder. Behav Ther 2001; 32: 235–58CrossRefGoogle Scholar
  13. 13.
    Fava GA. Conflict of interest and special interest groups. Psychother Psychosom 2001; 70: 1–5PubMedCrossRefGoogle Scholar
  14. 14.
    Garfinkel PE. The changing culture related to the practice of psychiatry. Psychother Psychosom 2001; 70: 227–31PubMedCrossRefGoogle Scholar
  15. 15.
    Starcevic V. Opportunistic “rediscovery” of mental disorders by pharmaceutical industry. Psychother Psychosom 2002; 71: 305–10PubMedCrossRefGoogle Scholar
  16. 16.
    Krimsky S. Journal policies on conflict of interest: if this is the therapy, what’s the disease? Psychother Psychosom 2001; 70: 115–7PubMedCrossRefGoogle Scholar
  17. 17.
    Ellis PM, Smith DAR. Treating depression: the beyond blue guidelines for treating depression in primary care. Med J Aust 2002; 176(10 Suppl.): S77–83PubMedGoogle Scholar
  18. 18.
    Thase ME, Sullivan LR. Relapse and recurrence of depression. CNS Drugs 1995; 4: 261–77CrossRefGoogle Scholar
  19. 19.
    Frank E, Kupfer DJ, Perel JM, et al. Three-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47: 1093–9PubMedCrossRefGoogle Scholar
  20. 20.
    Kupfer DJ. Maintenance treatment in recurrent depression. Br J Psychiatry 1992; 161: 309–16PubMedCrossRefGoogle Scholar
  21. 21.
    Geddes JR, Carney SM, Davies C, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361: 653–61PubMedCrossRefGoogle Scholar
  22. 22.
    Edwards JG. Long-term pharmacotherapy of depression. BMJ 1998; 316: 1180–1PubMedCrossRefGoogle Scholar
  23. 23.
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders: antidepressant and antianxiety agents. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 485–520Google Scholar
  24. 24.
    Kupfer DJ, Frank E, Perel JM, et al. Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49: 769–73PubMedCrossRefGoogle Scholar
  25. 25.
    Thornton A, Lee P. Publication bias in meta-analysis: its causes and consequences. J Clin Epidemiol 2000; 53: 207–16PubMedCrossRefGoogle Scholar
  26. 26.
    Otto MW, Nierenberg AA. Assay sensitivity, failed trials, and the conduct of science. Psychother Psychosom 2002; 71: 241–3PubMedCrossRefGoogle Scholar
  27. 27.
    Dawson R, Lavori PW, Coryell WH, et al. Maintenance strategies for unipolar depression. J Affect Disord 1998; 49: 31–44PubMedCrossRefGoogle Scholar
  28. 28.
    Fava GA, Mangelli L, Ruini C. Assessment of psychological distress in the setting of medical disease. Psychother Psychosom 2001; 70: 171–5PubMedCrossRefGoogle Scholar
  29. 29.
    Mischoulon D, McColl-Vuolo F, Howarth S,et al. Management of major depression in the primary care setting. Psychother Psychosom 2001; 70: 103–7PubMedCrossRefGoogle Scholar
  30. 30.
    Viguera AC, Baldessarini RJ, Friedberg J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293–306PubMedCrossRefGoogle Scholar
  31. 31.
    Baldessarini RJ, Ghaemi SN, Viguera AC. Tolerance in antidepressant treatment. Psychother Psychosom 2002; 71: 177–9PubMedCrossRefGoogle Scholar
  32. 32.
    Paykel ES, Tanner J. Life events, depressive relapse and maintenance treatment. Psychol Med 1976; 6: 481–5PubMedCrossRefGoogle Scholar
  33. 33.
    Andrews G. Should depression be managed as a chronic disease? BMJ 2001; 322: 419–21PubMedCrossRefGoogle Scholar
  34. 34.
    Fava GA, Ruini C, Mangelli L. Patients can be taught how to improve recovery [letter]. BMJ 2001; 322: 1428PubMedCrossRefGoogle Scholar
  35. 35.
    Byrne SE, Rothschild AJ. Loss of antidepressant efficacy during maintenance therapy. J Clin Psychiatry 1998; 59: 279–88PubMedCrossRefGoogle Scholar
  36. 36.
    Schmidt ME, Fava M, Zhang S, et al. Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Psychother Psychosom 2002; 71: 190–4PubMedCrossRefGoogle Scholar
  37. 37.
    Frank E, Kupfer DJ, Perel JM, et al. Comparison of full dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord 1993; 27:139–45PubMedCrossRefGoogle Scholar
  38. 38.
    Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100: 406–17PubMedCrossRefGoogle Scholar
  39. 39.
    Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology 1989; 98: 535–8PubMedCrossRefGoogle Scholar
  40. 40.
    Solomon DA, Keitner GI, Miller IW, et al. Course of illness and maintenance treatments for patients with bipolar disorder. J Clin Psychiatry 1995; 56: 5–13PubMedGoogle Scholar
  41. 41.
    Fava GA, Molnar G, Grandi S, et al. Prodromal symptoms and intermittent drug medication in mood disorders. Pharmacopsychiatry 1991; 24: 28–30PubMedCrossRefGoogle Scholar
  42. 42.
    Kupfer DJ, Frank E, Perel JM. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry 1989; 46: 771–5PubMedCrossRefGoogle Scholar
  43. 43.
    Streja DA, Hui RL, Streja E, et al. Selective contracting and patients outcomes. Am J Manag Care 1999; 5: 1133–42PubMedGoogle Scholar
  44. 44.
    Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48: 1420–6PubMedGoogle Scholar
  45. 45.
    Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care. JAMA 1996; 275: 1897–902PubMedCrossRefGoogle Scholar
  46. 46.
    Dunn RL, Donoghue JM, Ozminkowski RJ, et al. Longitudinal patterns of antidepressant prescribing in primary care in the UK. J Psychopharmacol 1999; 13: 136–43PubMedCrossRefGoogle Scholar
  47. 47.
    Fava GA, Rafanelli C, Grandi S, et al. Six year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998; 155: 1443–7PubMedGoogle Scholar
  48. 48.
    Fava M, Schmidt ME, Zhang S, et al. Treatment approaches to major depressive disorder relapse. Part II: re-initiation of antidepressant treatment. Psychother Psychosom 2002; 71: 155–99Google Scholar
  49. 49.
    Disalver SC. Heterocyclic antidepressant, monoamine oxidase inhibitor and neuroleptic withdrawal phenomena. Prog Neuro-psychopharmacol Biol Psychiatry 1999; 14: 137–61Google Scholar
  50. 50.
    Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors. J Clin Psychiatry 1997; 58: 291–7PubMedCrossRefGoogle Scholar
  51. 51.
    Fava GA, Ruini C. The sequential approach to relapse prevention in unipolar depression. World Psychiatry 2002; 1: 10–5PubMedGoogle Scholar
  52. 52.
    Fava GA, Rafanelli C, Grandi S, et al. Prevention of recurrent depression with cognitive behavioral therapy. Arch Gen Psychiatry 1998; 55: 816–20PubMedCrossRefGoogle Scholar
  53. 53.
    Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy in out-patients with recurrent depression. Br J Psychiatry 1997; 171: 328–34PubMedCrossRefGoogle Scholar
  54. 54.
    Paykel ES, Scott J, Teasdale JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry 1999; 56: 829–35PubMedCrossRefGoogle Scholar
  55. 55.
    Teasdale JD, Segal ZV, Williams JMG, et al. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000; 68: 615–23PubMedCrossRefGoogle Scholar
  56. 56.
    Jarrett RB, Kraft D, Doyle J, et al. Preventing recurrent depression using cognitive therapy with and without a continuation phase. Arch Gen Psychiatry 2001; 58: 381–8PubMedCrossRefGoogle Scholar
  57. 57.
    Jarrett RB, Kraft D, Schaffer M, et al. Reducing relapse in depressed out-patients with atypical features. Psychother Psychosom 2000; 69: 232–4PubMedCrossRefGoogle Scholar
  58. 58.
    Fava GA, Bartolucci G, Rafanelli C, et al. Cognitive behavioral management of patients with bipolar disorders relapsing while on lithium prophylaxis. J Clin Psychiatry 2001; 62: 556–9PubMedCrossRefGoogle Scholar
  59. 59.
    Fava GA, Ruini C, Rafanelli C, et al. Cognitive behavioral approach to loss of clinical effect during long-term antidepressant treatment. Am J Psychiatry 2002; 159: 2094–5PubMedCrossRefGoogle Scholar
  60. 60.
    Fava GA, Fabbri S, Sonino N. Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsycho-pharmacol Biol Psychiatry 2002; 26: 1019–27CrossRefGoogle Scholar
  61. 61.
    Barbui C, Hotopf M. Amitriptyline versus the rest. Br J Psychiatry 2001; 178: 129–44PubMedCrossRefGoogle Scholar
  62. 62.
    Faravelli C, Cosci F, Ciampelli M, et al. A self-controlled, naturalistic study of selective serotonin reuptake inhibitors versus tricyclic antidepressants. Psychother Psychosom 2003; 72: 95–101PubMedCrossRefGoogle Scholar
  63. 63.
    Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–41PubMedCrossRefGoogle Scholar
  64. 64.
    Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiat Clin N Am 1996; 19: 179–200CrossRefGoogle Scholar
  65. 65.
    Sonino N, Fava GA. CNS drugs in Cushing’s disease: pathophysiological and therapeutic implications for mood disorders. Prog Neuropsycopharmacol Biol Psychiatry 2002; 26: 1011–8CrossRefGoogle Scholar
  66. 66.
    Sonino N, Fava FA. Tolerance to antidepressant treatment may be overcome by ketoconazole. J Psychiatr Res 2003; 37: 171–3PubMedCrossRefGoogle Scholar
  67. 67.
    Morris MS, Fava M, Jacques PF, et al. Depression and folate status in the US population. Psychother Psychosom 2003; 72: 80–7PubMedCrossRefGoogle Scholar
  68. 68.
    Bjelland I, Ueland PM, Vollset SE. Folate and depression. Psychother Psychosom 2003; 72: 59–60PubMedCrossRefGoogle Scholar
  69. 69.
    Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 3719-3030: global burden of disease study. Lancet 1997; 349: 1498–504PubMedCrossRefGoogle Scholar
  70. 70.
    Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–56PubMedCrossRefGoogle Scholar
  71. 71.
    Ryff CD, Singer B. Psychological well-being. Psychother Psychosom 1996; 65: 14–23PubMedCrossRefGoogle Scholar
  72. 72.
    Fava GA. Long-term treatment with antidepressant drugs. Psychother Psychosom 2002; 71: 127–32PubMedCrossRefGoogle Scholar
  73. 73.
    Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry 2003; 64: 123–33PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Giovanni A. Fava
    • 1
  • Chiara Ruini
    • 1
  • Nicoletta Sonino
    • 2
    • 3
  1. 1.Affective Disorders Program, Department of PsychologyUniversity of BolognaBolognaItaly
  2. 2.Department of Statistical SciencesUniversity of PadovaPadovaItaly
  3. 3.Department of Mental HealthPadova City HospitalPadovaItaly

Personalised recommendations